Molecular Characteristics of Uveal Melanoma and Intraocular Tumors

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 Nov 26

PMID 33240415

Citations 4

Authors

Periklis Katopodis

Mohammad S Khalifa

Vladimir Anikin

Affiliations

Soon will be listed here.

Abstract

Malignant melanomas within the eye present different types of metabolic and metastatic behavior. Uveal melanoma (UM) affects a quarter of a million individuals in the USA; however, the molecular pathogenesis is not well understood. Although UV radiation is a risk factor in cutaneous melanomas, it is not crucial for UM progression. Apart from chromosomal abnormalities, numerous major tumorigenic signaling pathways, including the PI3K/Akt, MAPK/ERK, Ras-association domain family 1 isoform A and Yes-associated protein/transcriptional co-activator with PDZ-binding motif signaling pathways, are associated with intraocular tumors. The present review describes the current insights regarding these signaling pathways that regulate the cell cycle and apoptosis, and could be used as potential targets for the treatment of UMs.

Citing Articles

Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.

Beigi Y, Lanjanian H, Fayazi R, Salimi M, Hoseyni B, Noroozizadeh M Mol Biomed. 2024; 5(1):17.

PMID: 38724687 PMC: 11082128. DOI: 10.1186/s43556-024-00182-2.

Decoding tumor heterogeneity in uveal melanoma: basement membrane genes as novel biomarkers and therapeutic targets revealed by multi-omics approaches for cancer immunotherapy.

Li Y, Cai H, Yang J, Xie X, Pei S, Wu Y Front Pharmacol. 2023; 14:1264345.

PMID: 37822877 PMC: 10562578. DOI: 10.3389/fphar.2023.1264345.

Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma.

Sundaramurthi H, Giricz Z, Kennedy B Int J Mol Sci. 2022; 23(16).

PMID: 36012642 PMC: 9409113. DOI: 10.3390/ijms23169378.

MMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma.

Wang T, Zhang Y, Bai J, Xue Y, Peng Q BMC Cancer. 2021; 21(1):1068.

PMID: 34587931 PMC: 8482640. DOI: 10.1186/s12885-021-08788-3.

References

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Rayess H, Wang M, Srivatsan E . Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2011; 130(8):1715-25. PMC: 3288293. DOI: 10.1002/ijc.27316. View

Chua V, Lapadula D, Randolph C, Benovic J, Wedegaertner P, Aplin A . Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. Mol Cancer Res. 2017; 15(5):501-506. PMC: 5468095. DOI: 10.1158/1541-7786.MCR-17-0007. View

McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

Lundberg A, Weinberg R . Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998; 18(2):753-61. PMC: 108786. DOI: 10.1128/MCB.18.2.753. View

Mallet J, Gendron S, Desgarnier M, Rochette P . Implication of ultraviolet light in the etiology of uveal melanoma: A review. Photochem Photobiol. 2013; 90(1):15-21. DOI: 10.1111/php.12161. View

Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H . The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020; 21(6). PMC: 7139603. DOI: 10.3390/ijms21061960. View

Nayman T, Bostan C, Logan P, Burnier Jr M . Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses. Curr Eye Res. 2017; 42(8):1085-1093. DOI: 10.1080/02713683.2017.1297997. View

10.

Brantley Jr M, Harbour J . Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000; 157(6):1795-801. PMC: 1885790. DOI: 10.1016/s0002-9440(10)64817-1. View

11.

Plouffe S, Hong A, Guan K . Disease implications of the Hippo/YAP pathway. Trends Mol Med. 2015; 21(4):212-22. PMC: 4385444. DOI: 10.1016/j.molmed.2015.01.003. View

12.

Blain S, Scher H, Cordon-Cardo C, Koff A . p27 as a target for cancer therapeutics. Cancer Cell. 2003; 3(2):111-5. DOI: 10.1016/s1535-6108(03)00026-6. View

13.

Tschentscher F, Husing J, Holter T, Kruse E, Dresen I, Jockel K . Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003; 63(10):2578-84. View

14.

Chang H, Cai Z, Roberts T . The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules. 2019; 9(11). PMC: 6921025. DOI: 10.3390/biom9110713. View

15.

Zaman A, Wu W, Bivona T . Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019; 11(8). PMC: 6721448. DOI: 10.3390/cancers11081197. View

16.

Zenonos K, Kyprianou K . RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013; 5(5):97-101. PMC: 3682174. DOI: 10.4251/wjgo.v5.i5.97. View

17.

Bartek J, Bartkova J, Lukas J . The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res. 1998; 237(1):1-6. DOI: 10.1006/excr.1997.3776. View

18.

Soparker C, OBrien J, Albert D . Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci. 1993; 34(7):2203-9. View

19.

Shinozaki M, Fujimoto A, Morton D, Hoon D . Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004; 10(5):1753-7. DOI: 10.1158/1078-0432.ccr-1169-3. View

20.

Mooy C, Luyten G, de Jong P, Luider T, Stijnen T, van de Ham F . Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol. 1995; 147(4):1097-104. PMC: 1871011. View